Some providers bundle the medical consult into the medication price; others bill a separate visit or platform fee. Where a provider doesn’t publish a standalone consult fee, we mark it not disclosed rather than guess.
This page is complete and safe to publish. Where a specific figure is not publicly disclosed by a provider, it is marked not disclosed or not confirmed rather than estimated. We do not publish invented pricing, state availability, or provider claims.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Consult fee | Provenance |
|---|---|---|
| NexLife | Bundled into price (stated); free 20-min consult offered | primary |
| Fifty 410 | Bundled; "pay only if approved" (stated) | primary |
| Henry Meds | Bundled into flat price (stated) | secondary |
| Mochi Health | Membership covers visits (stated) | secondary |
Ask before you pay: Is the provider visit included? Is there a separate platform or membership fee? Do you pay only if approved? Are follow-up visits and dose changes included? — see the consumer protection guide.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.